Volume 82, Issue 3, Pages (August 2012)

Slides:

Advertisements

Similar presentations

Volume 82, Issue 12, Pages (December 2012)

Advertisements

Vitamin D levels and patient outcome in chronic kidney disease

Improved prognosis of diabetic nephropathy in type 1 diabetes

LDL cholesterol in CKD—to treat or not to treat?

Beta blockers in the management of chronic kidney disease

Volume 84, Issue 2, Pages (August 2013)

Urinary ammonia and long-term outcomes in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease Kevin E. Chan, Ravi I. Thadhani,

Volume 83, Issue 3, Pages (March 2013)

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy Misghina Weldegiorgis, Dick de Zeeuw, Liang Li,

Rajiv Agarwal, John W. Kusek, Maria K. Pappas Kidney International

Volume 80, Issue 1, Pages (July 2011)

John P. Middleton, Patrick H. Pun Kidney International

Volume 82, Issue 12, Pages (December 2012)

Volume 81, Issue 7, Pages (April 2012)

Volume 86, Issue 4, Pages (October 2014)

Need for better diabetes treatment for improved renal outcome

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 80, Issue 9, Pages (November 2011)

Volume 57, Pages S32-S37 (April 2000)

GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta- analysis of Treatment Effects From 37 Randomized Trials Lesley A.

Comorbidity and confounding in end-stage renal disease

Steven J. Rosansky, Richard J. Glassock Kidney International

Volume 74, Issue 3, Pages (August 2008)

Ananda Chapagain, Hamish Dobbie, Michael Sheaff, Muhammad M. Yaqoob

Volume 91, Issue 1, Pages (January 2017)

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Volume 79, Issue 9, Pages (May 2011)

Volume 85, Issue 6, Pages (June 2014)

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor.

U-shaped effect of eGFR and mortality

Volume 76, Issue 10, Pages (November 2009)

LDL cholesterol in CKD—to treat or not to treat?

Volume 83, Issue 4, Pages (April 2013)

Volume 70, Issue 12, Pages (December 2006)

Volume 65, Issue 6, Pages (June 2004)

Volume 69, Issue 9, Pages (May 2006)

Volume 81, Issue 6, Pages (March 2012)

Vitamin D levels and patient outcome in chronic kidney disease

Volume 74, Issue 3, Pages (August 2008)

Methods for guideline development

Volume 87, Issue 1, Pages (January 2015)

Volume 84, Issue 5, Pages (November 2013)

Volume 76, Issue 8, Pages (October 2009)

The kidney, a cardiovascular risk marker, and a new target for therapy

Atrial fibrillation in end-stage renal disease: an emerging problem

Volume 80, Issue 6, Pages (September 2011)

Volume 74, Issue 5, Pages (September 2008)

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Improved prognosis of diabetic nephropathy in type 1 diabetes

Volume 85, Issue 5, Pages (May 2014)

Volume 73, Issue 8, Pages (April 2008)

Volume 80, Issue 3, Pages (August 2011)

Volume 81, Issue 7, Pages (April 2012)

Volume 87, Issue 1, Pages (January 2015)

Carmine Zoccali, Francesca Mallamaci Kidney International

Low triiodothyronine and survival in end-stage renal disease

Volume 76, Issue 6, Pages (September 2009)

Volume 83, Issue 3, Pages (March 2013)

Volume 80, Issue 10, Pages (November 2011)

Volume 81, Issue 7, Pages (April 2012)

Michael R. Lattanzio, Matthew R. Weir Kidney International

Volume 75, Issue 1, Pages (January 2009)

Volume 75, Issue 7, Pages (April 2009)

Adiponectin: good, bad, or just plain ugly?

Friends, social networks, and progressive chronic kidney disease

Volume 57, Issue 2, Pages (October 2000)

Effect of randomized treatment on all renal events (top) and the composite of all renal events, macrovascular events, or all-cause mortality (bottom) according.

Presentation transcript:

Volume 82, Issue 3, Pages 330-337 (August 2012) Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers Hiddo J. Lambers Heerspink, Frank A. Holtkamp, Hans-Henrik Parving, Gerjan J. Navis, Julia B. Lewis, Eberhard Ritz, Pieter A. de Graeff, Dick de Zeeuw Kidney International Volume 82, Issue 3, Pages 330-337 (August 2012) DOI: 10.1038/ki.2012.74 Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 1 Kaplan–Meier curves according to tertiles of 24-h urinary sodium/creatinine ratio. Kaplan–Meier curves for (a) renal and (b) cardiovascular events in subjects who received angiotensin receptor blocker (ARB)– and non-renin–angiotensin–aldosterone system (non-RAASi)–based therapy stratified by tertiles of 24-h sodium/creatinine ratio: <121mmol/g; 121–153mmol/g; ≥153mmol/g. Kidney International 2012 82, 330-337DOI: (10.1038/ki.2012.74) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 2 Effect of angiotensin receptor blocker (ARB) treatment vs. non-renin–angiotensin–aldosterone system (non-RAASi)–based treatment on the risk for renal and cardiovascular outcomes according to tertiles of 24-h urinary sodium/creatinine ratio. The center of the diamond represents the overall estimate, and the width represents its 95% confidence interval (CI). Solid boxes represent estimates of treatment effects in subgroups, and the horizontal line represents the 95% CI. ESRD, end-stage renal disease. Kidney International 2012 82, 330-337DOI: (10.1038/ki.2012.74) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 3 Mean estimated glomerular filtration rate (eGFR) levels through 30 months among patients who were assigned to receive angiotensin receptor blocker (ARB) or non-renin–angiotensin–aldosterone system (non-RAASi)–based therapy by tertiles of 24-h sodium/creatinine ratio. Kidney International 2012 82, 330-337DOI: (10.1038/ki.2012.74) Copyright © 2012 International Society of Nephrology Terms and Conditions